Warning: The NCBI web site requires JavaScript to function. more...
Policy makers ignoring science and scientists ignoring policy: the medical ethical challenges of heroin treatment.
Small D, Drucker E; Editorial for Harm Reduction Journal.
Harm Reduct J. 2006 May 2;3:16.
Related citations
A tribute to a gifted scholar, Anne Hudson, who has made revolutionary advances in healthcare and patient safety in our nation.
Edlich RF.
J Long Term Eff Med Implants. 2006;16(3):207-22.
ISA 247: trans-ISA 247, trans-R 1524, ISA(TX)247, ISAtx 247, ISATx247, LX 211, LX211, R 1524, R-1524.
[No authors listed]
Drugs R D. 2007;8(2):103-12. Review.
INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
Drugs R D. 2007;8(3):176-87. Review.
Heroin-assisted treatment (HAT) a decade later: a brief update on science and politics.
Fischer B, Oviedo-Joekes E, Blanken P, Haasen C, Rehm J, Schechter MT, Strang J, van den Brink W.
J Urban Health. 2007 Jul;84(4):552-62. Review.
KSR v. Teleflex. Part 2: Impact of U.S Supreme Court Patent Law on Canadian and global systems-based innovation ecologies.
Bouchard RA.
Health Law J. 2007;15:247-94.
Feasibility and outcomes of paid undergraduate student nurse positions.
Gamroth L, Budgen C, Lougheed M.
Nurs Leadersh (Tor Ont). 2006 Sep;19(3):e1-14.
NAOMI: The trials and tribulations of implementing a heroin assisted treatment study in North America.
Gartry CC, Oviedo-Joekes E, Laliberté N, Schechter MT.
Harm Reduct J. 2009 Jan 21;6:2.
Controlled trial of prescribed heroin in the treatment of opioid addiction.
March JC, Oviedo-Joekes E, Perea-Milla E, Carrasco F; PEPSA team.
J Subst Abuse Treat. 2006 Sep;31(2):203-11. Epub 2006 Jul 18.
Results of the first North American prescription heroin study are promising.
Symington A.
HIV AIDS Policy Law Rev. 2008 Dec;13(2-3):11-2.
Consideration of a North American heroin-assisted clinical trial for the treatment of opiate-dependent individuals.
Kuo I I, Fischer B, Vlahov D.
Int J Drug Policy. 2000 Sep 1;11(5):357-370.
Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE, Kleijnen J.
Eur J Health Econ. 2008 Nov;9 Suppl 1:5-29.
Prostate cancer disparities in South Carolina: early detection, special programs, and descriptive epidemiology.
Drake BF, Keane TE, Mosley CM, Adams SA, Elder KT, Modayil MV, Ureda JR, Hebert JR.
J S C Med Assoc. 2006 Aug;102(7):241-9. Review.
Prevention of suicide and attempted suicide in Denmark. Epidemiological studies of suicide and intervention studies in selected risk groups.
Nordentoft M.
Dan Med Bull. 2007 Nov;54(4):306-69. Review.
Heroin maintenance treatment: from idea to research to practice.
Uchtenhagen AA.
Drug Alcohol Rev. 2011 Mar;30(2):130-7. doi: 10.1111/j.1465-3362.2010.00266.x. Review.
[Procedures and methods of benefit assessments for medicines in Germany].
Dtsch Med Wochenschr. 2008 Dec;133 Suppl 7:S225-46. Epub 2008 Nov 25. German.
Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
Drugs R D. 2007;8(5):321-34. Review.
Conflicts of interest in research involving human beings.
Greco D, Diniz NM.
J Int Bioethique. 2008 Mar-Jun;19(1-2):143-54, 202-3. Review.
Vernakalant: RSD 1235, RSD-1235, RSD1235.
Drugs R D. 2007;8(4):259-65. Review.
Development of pharmaceutical heroin preparations for medical co-prescription to opioid dependent patients.
Klous MG, Van den Brink W, Van Ree JM, Beijnen JH.
Drug Alcohol Depend. 2005 Dec 12;80(3):283-95. Review.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on